The first biosimilar was approved in the U.S. in 2015. And now, just over 10 years later, the U.S. Food & Drug Administration (FDA) has approved an additional 81 biosimilars. In 2025 alone, the FDA approved 18 new biosimilars for a range of indications. However, only 73% of those approved biosimilars have been launched as of September 2025.  Last year, the  U.S. market size for biosimilars was estimated to be $22.59 billion….